Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.

Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses.

Many of the cost-effectiveness analyses of apixaban against warfarin focused on Western populations but Asian evidence remains less clear. The present study aims to evaluate the cost-effectiveness of apixaban against warfarin in Chinese patients with non-valvular atrial fibrillation (NVAF) from a pu...

Full description

Bibliographic Details
Main Authors: Xue Li, Vicki C Tse, Wallis C Y Lau, Bernard M Y Cheung, Gregory Y H Lip, Ian C K Wong, Esther W Chan
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2016-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4928891?pdf=render

Internet

http://europepmc.org/articles/PMC4928891?pdf=render

Similar Items